Listen
ENHERTU (trastuzumab deruxtecan) - Lung cancer
Opinions on drugs -
Posted on
Jul 18 2024
Reason for request
Indication extension
Summary of opinion
Unfavourable opinion for reimbursement in “the treatment of adult patients with NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy”.
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of ENHERTU (trastuzumab deruxtecan) is insufficient to justify public funding cover in the MA indication in view of the available alternatives. |
Clinical Added Value
| Not applicable |
English version
Contact Us
Évaluation des médicaments
